CST 2032/nadolol
Alternative Names: CST-2032/CST-107; CST-2032/Naldol - Curasen Theraepeutics; CST2032/nadololLatest Information Update: 12 Mar 2024
At a glance
- Originator CuraSen Therapeutics
- Class Antidementias; Antihypertensives; Antimigraines; Class II antiarrhythmics; Ischaemic heart disorder therapies; Neuroprotectants; Propanolamines; Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists; Beta adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Dementia; Mild cognitive impairment
Most Recent Events
- 07 Mar 2024 Efficacy and adverse event data from phase IIa trial in Mild cognitive impairment and Dementia released by
- 07 Mar 2024 CuraSen Therapeutics plans additional phase II trial for Mild Cognitive Impairment or Dementia from either Alzheimer’s or Parkinson’s disease
- 31 Mar 2023 Efficacy and safety results were released by CuraSen Therapeutics